文献速递神经创伤神经重症

GSK'872通过将受体相互作用丝氨酸/苏氨酸蛋白激酶3依赖性坏死性凋亡转换为半胱氨酰天冬氨酸特异性蛋白酶8依赖性凋亡改善创伤性脑损伤预后

GSK'872 Improves Prognosis of Traumatic Brain Injury by Switching Receptor-Interacting Serine/Threonine-Protein Kinase 3-dependent Necroptosis to Cysteinyl Aspartate Specific Proteinase-8-Dependent Apoptosis.
PubMed 文献 · World Neurosurg · 2024-04-17

本研究在体外细胞牵张损伤和体外小鼠控制性皮层撞击创伤性脑损伤模型中评估RIP3介导的坏死性凋亡的作用。结果显示,RIP1、RIP3和混合谱系激酶结构域样蛋白介导的坏死性凋亡参与继发性创伤性脑损伤,GSK'872抑制RIP3可阻断坏死性凋亡、降低Akt/mTOR活性、减轻炎症并促进半胱氨酰天冬氨酸特异性蛋白酶8活性,从而改善创伤性脑损伤预后。

要点

  • RIP1、RIP3和混合谱系激酶结构域样蛋白介导的坏死性凋亡参与继发性创伤性脑损伤。
  • GSK'872抑制RIP3可阻断坏死性凋亡并降低Akt/mTOR活性,从而减轻炎症。
  • RIP3抑制通过将RIP3依赖性坏死性凋亡转换为半胱氨酰天冬氨酸特异性蛋白酶8依赖性凋亡改善创伤性脑损伤预后。

核心结论

  • RIP3抑制可通过将RIP3依赖性坏死性凋亡转换为半胱氨酰天冬氨酸特异性蛋白酶8依赖性凋亡减轻炎症,从而改善创伤性脑损伤预后。

研究设计与样本

  • 研究建立体外细胞牵张损伤模型和体外小鼠控制性皮层撞击创伤性脑损伤模型,评估坏死性凋亡、凋亡、炎症与创伤性脑损伤的关系。

主要发现

  • RIP1、RIP3和混合谱系激酶结构域样蛋白介导的坏死性凋亡参与继发性创伤性脑损伤。
  • 蛋白激酶B、磷酸化蛋白激酶B、哺乳动物雷帕霉素靶蛋白和磷酸化哺乳动物雷帕霉素靶蛋白可能参与坏死性凋亡。
  • GSK'872抑制RIP3可阻断坏死性凋亡并降低Akt/mTOR活性,通过降低NOD样受体热蛋白结构域相关蛋白3水平减轻炎症。
  • GSK'872抑制RIP3可促进参与凋亡和炎症的半胱氨酰天冬氨酸特异性蛋白酶8活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traumatic brain injury (TBI) is an important health concern in the society. Previous studies have suggested that necroptosis occurs following TBI. However, the underlying mechanisms and roles of necroptosis are not well understood. In this study, we aimed to assess the role of receptor-interacting serine/threonine-protein kinase 3 (RIP3)-mediated necroptosis after TBI both in vitro and in vivo. METHODS: We established a cell-stretching injury and mouse TBI model by applying a cell injury controller and controlled cortical impactor to evaluate the relationships among necroptosis, apotosis, inflammation, and TBI both in vitro and in vivo. RESULTS: The results revealed that necroptosis mediated by RIP1, RIP3, and mixed lineage kinase domain-like protein was involved in secondary TBI. Additionally, protein kinase B (Akt), phosphorylated Akt, mammalian target of rapamycin (mTOR), and phosphorylated mTOR potentially contribute to necroptosis. The inhibition of RIP3 by GSK'872 (a specific inhibitor) blocked necroptosis and reduced the activity of Akt/mTOR, leading to the alleviation of inflammation by reducing the levels of NOD-, LRR- and pyrin domain-containing protein 3. Moreover, the inhibition of RIP3 by GSK'872 promoted the activity of cysteinyl aspartate specific proteinase-8, an enzyme involved in apoptosis and inflammation. CONCLUSIONS: These data demonstrate that RIP3 inhibition could improve the prognosis of TBI, based on the attenuation of inflammation by switching RIP3-dependent necroptosis to cysteinyl aspartate specific proteinase-8-dependent apoptosis.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Min Y, Yu ZQ. GSK'872 Improves Prognosis of Traumatic Brain Injury by Switching Receptor-Interacting Serine/Threonine-Protein Kinase 3-dependent Necroptosis to Cysteinyl Aspartate Specific Proteinase-8-Dependent Apoptosis. World Neurosurg. 2024. PMID: 38636634. doi:10.1016/j.wneu.2024.04.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。